Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Primary Inclusion Criteria: * At least 20 years of age * Histologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinoma. * Measurable disease (revised RECIST) based on computed tomography, or nonmeasurable disease * Previously untreated, unresectable advanced (M0) or unresectable metastatic (M1) disease except for prior adjuvant (or neo-adjuvant) chemotherapy. * ECOG performance status 0 or 1 * At least 4 weeks and recovery from effects of prior major surgery * Adequate bone marrow, hepatic, and renal function Primary Exclusion Criteria: * Operable gastric or gastroesophageal-junction cancer * Known brain metastasis * Second cancer * Previous adjuvant or neo-adjuvant chemotherapy with capecitabine and cisplatin in combination. (Previous adjuvant or neo-adjuvant monotherapy with capecitabine or S-1 or therapy with S-1 and cisplatin in combination or 5-FU and cisplatin in combination is allowed.) * Uncontrolled diarrhea * Nausea or vomiting for at least 3 consecutive days within the 14 days prior to registration despite the administration of standard antiemetic therapy * Symptomatic peripheral neuropathy ≥ Grade 2 * Malabsorption syndrome or other disease that significantly affects gastrointestinal function * Other uncontrolled systemic illness